ERVH-1

Across TCGA pan-cancer cohorts, ERVH-1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ERVH-1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ERVH-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ERVH-1 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

HNSC, COAD, and READ are the cancer types where ERVH-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERVH-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.059	.001	11	view →
COAD	Female	II,III,IV	−1.444	<.001	10	view →
READ	Male	All	−1.810	<.001	7	view →
KIRP	All	All	+1.637	<.001	7	view →
LIHC	All	All	+0.100	.001	7	view →
LUSC	All	III,IV	+0.165	.004	6	view →
KICH	All	All	−1.345	<.001	5	view →
BRCA	All	II,III,IV	−0.030	.002	4	view →
KIRC	All	III,IV	−0.626	.012	2	view →
CHOL	Female	All	+0.270	.018	2	view →
PAAD	Female	All	−0.155	.047	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ERVH-1–HNSC

Open the HNSC breakdown →